NCT05764317View on ClinicalTrials.gov

Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)

CompletedOBSERVATIONAL
Enrollment

409

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

February 20, 2024

Conditions
Arterial HypertensionHTN
Interventions
DRUG

Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 5 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

DRUG

Amlodipine 5 mg + atorvastatin 20 mg + perindopril arginine 10 mg

a triple fixed combination of atorvastatin, perindopril and amlodipinedose combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation

Trial Locations (1)

125196

Servier, Moscow

All Listed Sponsors
lead

Servier Russia

INDUSTRY